학술논문
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, March 2020, 21(3):345-357)
Subject
Language
English
ISSN
14745488
14702045
14702045